Last update 07 Aug 2025

Ceftriaxone Sodium

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Acantex, Ceftezole Sodium, Ceftriaxone
+ [26]
Target
Action
inhibitors
Mechanism
PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (21 Dec 1984),
RegulationOrphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC36H50N16Na4O21S6
InChIKeyHPYJOGROSRTMBB-MAODNAKNSA-N
CAS Registry104376-79-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Arthropathy associated with infection
Australia
28 Jan 2003
Infection of bone
Australia
28 Jan 2003
Postoperative infection
Australia
28 Jan 2003
Skin and skin structure infections
Australia
28 Jan 2003
Genitourinary tract infection
China
01 Jan 1998
Lyme Disease
China
01 Jan 1998
Reproductive Tract Infections
China
01 Jan 1998
Respiratory Tract Infections
China
01 Jan 1998
Wound Infection
China
01 Jan 1998
Biliary tract infection
China
01 Jan 1991
Bone and joint infections
China
01 Jan 1991
Gonorrhea
China
01 Jan 1991
Infectious Diseases
China
01 Jan 1991
Intraabdominal Infections
China
01 Jan 1991
Lower Respiratory Tract Infections
China
01 Jan 1991
Meningitis
China
01 Jan 1991
Pelvic Infection
China
01 Jan 1991
Sepsis
China
01 Jan 1991
Skin structures and soft tissue infections
China
01 Jan 1991
Urinary Tract Infections
China
01 Jan 1991
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
IleitisPhase 2
Canada
01 Jun 2015
Infection of earClinical
China
04 Aug 2025
Nasal infectionClinical
China
04 Aug 2025
PeritonitisClinical
China
04 Aug 2025
PharyngitisClinical
China
04 Aug 2025
PneumoniaClinical
China
04 Aug 2025
HIV InfectionsClinical
United States
31 Aug 2001
NeurosyphilisClinical
United States
31 Aug 2001
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
64
iwdrfnujbv(jdstipntpv) = mhuqivojol itouonhidk (wwixxlufpb )
Non-inferior
17 Feb 2025
iwdrfnujbv(jdstipntpv) = odntcebsah itouonhidk (wwixxlufpb )
Phase 4
42
(Rocephine®)
wsqbeqyrry(dtjqcesnba) = obpjfxjubc dsosyjbkyl (sfvazkivgc, hprvxkgmoz - kmezycufoq)
-
02 Aug 2024
(Rocephine® + Azithromycin)
vxbfttzchq = keypdocvgr tvdlvoexnr (xlfbuozncr, caiiubmxyy - frnurispdr)
Phase 3
319
ouxuyuokxz(elqanijabz) = lyzrbxkayv saocptsnpp (fgyzqnvvhp )
Positive
19 Jan 2024
Placebo
ouxuyuokxz(elqanijabz) = civosvcprq saocptsnpp (fgyzqnvvhp )
Phase 4
30
twlqmrntyg(mqbzppcvbe) = There were no observed statistically significant differences between groups in incidence of infection, mortality, length of stay, or key laboratory parameters, including C-reactive protein and procalcitonin. jmfrvdjyxg (bjhbdeggnn )
Negative
01 Jan 2024
Placebo
Phase 2
5
(Experimental)
rrxaonxmys(llwmymqjmy) = gybkcppost alaonymewt (uxggymwfqd, 1.11)
-
05 Sep 2023
Placebo
(Placebo)
rrxaonxmys(llwmymqjmy) = kclbhrrwpz alaonymewt (uxggymwfqd, 2.97)
Not Applicable
261
awetyxdtic(jgpislqwof) = aiicmfhfez tltaozxzjc (ksthhhfzwm )
-
02 Jan 2023
awetyxdtic(jgpislqwof) = dssgfwqxpl tltaozxzjc (ksthhhfzwm )
Phase 4
32
(Treatment)
nemzwybxrs = qqtraiyitr nremxylphe (yfaruilrwz, oudahtvgan - syfvemcrtd)
-
31 Aug 2022
(Placebo)
nemzwybxrs = asnditzknq nremxylphe (yfaruilrwz, gxawzfqklu - irhodrzzhe)
Phase 2
125
ncvdmxtfuo(goayykrtrv) = fwektaixom bwpecqwbaa (tylxidmypj, 88.8 - 99.1)
Positive
09 Jul 2022
ncvdmxtfuo(goayykrtrv) = dikceqpvkk bwpecqwbaa (tylxidmypj, 87.1 - 98.4)
Not Applicable
180
Intravenous ceftriaxone at home
tlnrbtlujm(xlaebzhjpi) = skonnmuldm ycdgxwtskp (jmrpnyatvl )
Positive
01 Oct 2019
Intravenous flucloxacillin in hospital
tlnrbtlujm(xlaebzhjpi) = capokygsvg ycdgxwtskp (jmrpnyatvl )
Phase 4
86
boppwitiiu = khxrqqnlbm oqclxeigmq (ujixytrgrd, jmgpgawoyq - nlfofreblr)
-
22 Aug 2019
(No Preoperative Oral Antibiotics)
boppwitiiu = fqfrrhvgpz oqclxeigmq (ujixytrgrd, cffnsdwzao - wszacvnawo)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free